Jonas Neher

Prof. Dr. Jonas Neher serves as a Group Leader at the German Center for Neurodegenerative Diseases (DZNE) in Munich, where he leads research focused on the role of microglia and immune responses in neurodegenerative diseases, particularly Alzheimer's disease. His laboratory investigates how peripheral inflammation affects brain pathology through mechanisms like innate immune memory and epigenetic reprogramming.

Dr. Neher's research program centers on understanding how microglia contribute to Alzheimer's pathology, particularly amyloidosis and neuronal damage. He has demonstrated that microglia are capable of 'remembering' inflammatory insults through epigenetic reprogramming, creating long-term adaptations that significantly affect brain disease progression. His work has established innate immune memory as a previously unrecognized non-genetic risk factor for neurodegenerative diseases. Additionally, he studies vascular dysfunction in Alzheimer's disease, with a particular focus on medin amyloid, which is now recognized as a common factor in age-related arterial stiffening and a potential therapeutic target for millions affected by cognitive decline.

Analysis of Dr. Neher's publication record reveals a strong trajectory from fundamental immunological mechanisms to translational applications. His recent work (2022-2024) shows increasing focus on medin amyloid's role in vascular pathology, with high-impact publications in Nature and Nature Aging. His laboratory has developed specialized single-cell profiling techniques that combine transcriptomic and epigenetic analyses to better understand cellular heterogeneity in neurodegenerative conditions. This methodological innovation enables more precise characterization of microglial subtypes and their responses to inflammatory stimuli.

Dr. Neher leads an active research group investigating how peripheral inflammatory stimuli affect the brain's immune response and contribute to neurodegenerative disease pathology. His laboratory has developed specialized methods for profiling microglia and other brain cells at the single-cell level, combining transcriptomic and epigenetic analyses to better understand cellular heterogeneity in health and disease. His research bridges basic science with potential clinical applications, particularly in developing new therapeutic strategies targeting both immune and vascular components of Alzheimer's disease.